US 11,814,402 B2
Binuclear palladacycles and their use in the treatment of cancer
Angelique Blanckenberg, Somerset West (ZA); Annick Van Niekerk, Strand (ZA); Selwyn Frank Mapolie, Kensington (ZA); and Sharon Prince, Garlandale (ZA)
Assigned to Stellenbosch University, Stellenbosch (ZA); and University of Cape Town, Cape Town (ZA)
Appl. No. 16/960,967
Filed by Stellenbosch University, Stellenbosch (ZA); and University of Cape Town, Cape Town (ZA)
PCT Filed Feb. 15, 2019, PCT No. PCT/IB2019/051223
§ 371(c)(1), (2) Date Jul. 9, 2020,
PCT Pub. No. WO2019/159114, PCT Pub. Date Aug. 22, 2019.
Prior Publication US 2020/0339616 A1, Oct. 29, 2020
Int. Cl. C07F 15/00 (2006.01); A61P 35/00 (2006.01); A61K 31/66 (2006.01)
CPC C07F 15/006 (2013.01) [A61K 31/66 (2013.01); A61P 35/00 (2018.01)] 17 Claims
OG exemplary drawing
 
1. A compound of the Formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, stereoisomer, hydrate, or solvate thereof wherein,
R1 is phenyl optionally substituted with one or more substituents independently selected from linear or branched C1-4 alkyl, hydroxyl, and —SO3H,
R2 is independently selected from halogen, —NCS, —SCN, N3, and —OOCCH3, and —OS(CH3)2,
R is (CH2)y, wherein y is 1-3,
R3 is independently one or more substituents selected from hydrogen, and —O(CH2CH2O)xR4, provided that at least one R3 is not hydrogen, wherein x is 1-3,
R4 is independently selected from hydrogen, —CH2CH2OH, and —CH2CH2R5, a folic acid group, a monosaccharide group, a disaccharide group, and a fatty acid group,
R5 is C1-4 alkoxy.